Stock Rating Downgrade
Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Takeda Pharmaceutical Co Ltd (NYSE: TAK) weakened of late. TAK’s current Value Trend Rating is C and the prior Rating was B. Details supporting this lower rating are included in our next report.
Recent Price Action
On 5/31/24, Takeda Pharmaceutical Co Ltd (NYSE: TAK) stock enjoyed a large increase of 2.5%, closing at $13.35. NORMAL trading volume accompanied the advance. The stock has been weak relative to the market over the last nine months but has risen 2.2% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, TAK is expected to continue to be a Value Builder.
Takeda Pharmaceutical has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Takeda Pharmaceutical has a very high Appreciation Score of 94 but a poor Power Rating of 28, leading to the High Neutral Value Trend Rating.
Be the first to comment